Stein Hallan

Prof. Dr. Stein Hallan


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2006 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SHStein Hallan
Stein Hallan
JCJosef Coresh
Josef Coresh
BABrad C. Astor
Brad C. Astor
AAArne A[Combining Ring Above]Sberg
Arne A[Combining Ring Above]Sberg
NPNeil R. Powe
Neil R. Powe
JHJostein Holmen
Jostein Holmen
ESRD incidence is much lower in Europe compared with the United States. This study investigated whether this reflects a difference in the prevalence of earlier stages of chronic kidney disease (CKD) or other mechanisms. CKD prevalence in Norway was estimated from the population-based Health Survey of Nord-Trondelag County (HUNT II), which included 65,181 adults in 1995 through 1997 (participation rate 70.4%). Data were analyzed using the same methods as two US National Health and Nutrition Examination Surveys in 1988 through 1994 (n = 15,488) and 1999 through 2000 (n = 4101). The primary analysis used gender-specific cutoffs in estimating persistent albuminuria for CKD stages 1 and 2. ESRD rates and other relevant data were extracted from national registries. Total CKD prevalence in Norway was 10.2% (SE 0.5): CKD stage 1 (GFR >90 ml/min per 1.73 m2 and albuminuria), 2.7% (SE 0.3); stage 2 (GFR 60 to 89 ml/min per 1.73 m2 and albuminuria), 3.2% (SE 0.4); stage 3 (GFR 30 to 59 ml/min per 1.73 m2), 4.2% (SE 0.1); and stage 4 (GFR 15 to 29 ml/min per 1.73 m2), 0.2% (SE 0.01). This closely approximates reported US CKD prevalence (11.0% in 1988 through 1994 and 11.7% in 1999 through 2000). The relative risk for progression from CKD stages 3 or 4 to ESRD in US white patients compared with Norwegian patients was 2.5. This was only modestly modified by adjustment for age, gender, and diabetes. Age and GFR at start of dialysis were similar, hypertension and cardiovascular mortality in the populations were comparable, but US white patients were referred later to a nephrologist and had higher prevalence of obesity and diabetes. In conclusion, CKD prevalence in Norway was similar to that in the United States, suggesting that lower progression to ESRD rather than a smaller pool of individuals at risk accounts for the lower incidence of ESRD in Norway.

1 May 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SHStein Hallan
Stein Hallan
EREberhard Ritz
Eberhard Ritz
SLStian Lydersen
Stian Lydersen
SRSolfrid Romundstad
Solfrid Romundstad
KKKurt Kvenild
Kurt Kvenild
SOStephan R. Orth
Stephan R. Orth
Despite the high prevalence of chronic kidney disease (CKD), relatively few individuals with CKD progress to ESRD. A better understanding of the risk factors for progression could improve the classification system of CKD and strategies for screening. We analyzed data from 65,589 adults who participated in the Nord-Trøndelag Health (HUNT 2) Study (1995 to 1997) and found 124 patients who progressed to ESRD after 10.3 yr of follow-up. In multivariable survival analysis, estimated GFR (eGFR) and albuminuria were independently and strongly associated with progression to ESRD: Hazard ratios for eGFR 45 to 59, 30 to 44, and 15 to 29 ml/min per 1.73 m2 were 6.7, 18.8, and 65.7, respectively (P < 0.001 for all), and for micro- and macroalbuminuria were 13.0 and 47.2 (P < 0.001 for both). Hypertension, diabetes, male gender, smoking, depression, obesity, cardiovascular disease, dyslipidemia, physical activity and education did not add predictive information. Time-dependent receiver operating characteristic analyses showed that considering both the urinary albumin/creatinine ratio and eGFR substantially improved diagnostic accuracy. Referral based on current stages 3 to 4 CKD (eGFR 15 to 59 ml/min per 1.73 m2) would include 4.7% of the general population and identify 69.4% of all individuals progressing to ESRD. Referral based on our classification system would include 1.4% of the general population without losing predictive power (i.e., it would detect 65.6% of all individuals progressing to ESRD). In conclusion, all levels of reduced eGFR should be complemented by quantification of urinary albumin to predict optimally progression to ESRD.

24 October 2006 in BMJ
Verified
Journal Article
Open access
PDF file
SHStein Hallan
Stein Hallan
KDKetil Dahl
Ketil Dahl
COCecilia M Oien
Cecilia M Oien
DGDiana C Grootendorst
Diana C Grootendorst
AAArne Aasberg
Arne Aasberg
FDFriedo W Dekker
Friedo W Dekker
Objective To find an effective screening strategy for detecting patients with chronic kidney disease and to describe the natural course of the disease. Design Eight year follow-up of a cross sectional health survey (the HUNT II study). Setting Nord-Trøndelag County, Norway Participants 65 604 people (70.6 % of all adults aged ≥20 in the county). Main outcome measures Incident end stage renal disease (ESRD) and cardiovascular mortality monitored by individual linkage to central registries. Results 3069/65 604 (4.7%) people had chronic kidney disease (estimated glomerular filtration rate 55 would identify 93.2% (92.4% to 94.0%) of patients with chronic kidney disease, with a number needed to screen of 8.7 (8.5 to 9.0). Restriction of screening according to guidelines of the United States kidney disease outcomes quality initiative (US KDOQI) gave similar results, but restriction according to the United Kingdom's chronic kidney disease guidelines detected only 60.9% (59.1% to 62.8%) of cases. Screening only people with previously known diabetes or hypertension detected 44.2% (42.7% to 45.7%) of all cases, with a number needed to screen of six. During the eight year follow-up only 38 of the 3069 people with chronic kidney disease progressed to end stage renal disease, and the risk was especially low in people without diabetes or hypertension, women, and those aged ≥70 or with a glomerular filtration rate 45-59 ml/min/1.73 m2 at screening. In contrast, there was a high cardiovascular mortality: 3.5, 7.4, and 10.1 deaths per 100 person years among people with a glomerular filtration rate 45-59, 30-44, and 55 was the most effective strategy to detect patients with chronic kidney disease, but the risk of end stage renal disease among those detected was low.

10 December 2007 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
SHStein Hallan
Stein Hallan
BABrad Astor
Brad Astor
SRSolfrid Romundstad
Solfrid Romundstad
KAKnut Aasarød
Knut Aasarød
KKKurt Kvenild
Kurt Kvenild
JCJosef Coresh
Josef Coresh
Primary prevention of cardiovascular disease (CVD) in people 70 years or older is debated.1,2 Despite the fact that most of the cardiovascular morbidity, mortality, and costs occur at older ages, there are few data on the benefits and risks of the treatment, and we lack tools for accurate prediction of cardiovascular risk. Reduced kidney function and urinary excretion of albumin are used for defining and staging chronic kidney disease,3 a common condition with a high risk of CVD in addition to the risk of progression to end-stage renal disease.4-7 The interaction between the kidney and the heart increasingly emerges as an important factor for CVD,8 and kidney function and urinary excretion of albumin are now suggested as risk factors to be measured in assessing risk of cardiovascular death, in addition to hypertension, diabetes mellitus (DM), hypercholesterolemia, and smoking.9,10 However, these new, potentially related risk factors have seldom been evaluated together in population-based studies.

1 March 2006 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
SHStein Hallan
Stein Hallan
RMRenée de Mutsert
Renée de Mutsert
SCSven Carlsen
Sven Carlsen
FDFriedo W. Dekker
Friedo W. Dekker
KAKnut Aasarød
Knut Aasarød
JHJostein Holmen
Jostein Holmen

1 December 2017 in EBioMedicine
Verified
Journal Article
Open access
SHStein Hallan
Stein Hallan
MAMaryam Afkarian
Maryam Afkarian
LZLeila R. Zelnick
Leila R. Zelnick
BKBryan Kestenbaum
Bryan Kestenbaum
SSShoba Sharma
Shoba Sharma
IBIan H. de Boer
Ian H. de Boer
Chronic kidney disease (CKD) is a public health problem with very high prevalence and mortality. Yet, there is a paucity of effective treatment options, partly due to insufficient knowledge of underlying pathophysiology. We combined metabolomics (GCMS) with kidney gene expression studies to identify metabolic pathways that are altered in adults with non-diabetic stage 3-4 CKD versus healthy adults. Urinary excretion rate of 27 metabolites and plasma concentration of 33 metabolites differed significantly in CKD patients versus controls (estimate range-68% to +113%). Pathway analysis revealed that the citric acid cycle was the most significantly affected, with urinary excretion of citrate, cis-aconitate, isocitrate, 2-oxoglutarate and succinate reduced by 40-68%. Reduction of the citric acid cycle metabolites in urine was replicated in an independent cohort. Expression of genes regulating aconitate, isocitrate, 2-oxoglutarate and succinate were significantly reduced in kidney biopsies. We observed increased urine citrate excretion (+74%, p=0.00009) and plasma 2-oxoglutarate concentrations (+12%, p=0.002) in CKD patients during treatment with a vitamin-D receptor agonist in a randomized trial. In conclusion, urinary excretion of citric acid cycle metabolites and renal expression of genes regulating these metabolites were reduced in non-diabetic CKD. This supports the emerging view of CKD as a state of mitochondrial dysfunction.